ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 02, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a
biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that
Samarth Kulkarni, Ph.D., Chief Executive Officer, will present at the Chardan Genetic Medicines Conference on Tuesday, October 9,
2018 at 11:30 am ET.
A live webcast of the Chardan presentation will be available on the "Events & Presentations" page in the
Investors section of the company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the company's website
for 14 days following the presentation.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious
diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for
precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad
range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand
its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex
Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S.
subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London,
United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Investor Contact:
Susan Kim
susan.kim@crisprtx.com
CRISPR Media Contact:
Jennifer Paganelli
WCG on behalf of CRISPR
347-658-8290
jpaganelli@wcgworld.com
